A Prospective, Phase II Study to Evaluate Safety of 101-PGC-005 ('005) for Moderate to Severe COVID-19 Disease Along With Standard of Care
Clinical trial NCT05195749 · TERMINATED
Trial details
- NCT number
- NCT05195749
- Sponsor
- 101 Therapeutics
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-01-13
- Primary completion
- 2023-02-14
- Enrollment
- 3
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.